BioCryst Pharmaceuticals (BCRX) 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 31, 2020
Document Information [Line Items]
Entity Central Index Key	0000882796
Entity Registrant Name	BIOCRYST PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	000-23186
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	62-1413174
Entity Address, Address Line One	4505 Emperor Blvd., Suite 200
Entity Address, City or Town	Durham
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	859-1302
Title of 12(b) Security	Common Stock
Trading Symbol	BCRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		176,565,622

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	$ 96,492	$ 114,172
Restricted cash	2,213	1,551
Investments	46,827	22,054
Receivables from collaborations	5,422	22,146
Inventories	6,241	0
Prepaid expenses and other current assets	5,241	4,422
Total current assets	162,436	164,345
Investments	3,002	0
Property and equipment, net	7,142	7,347
Other assets	3,646	3,590
Total assets	176,226	175,282
Liabilities and Stockholders’ Equity
Accounts payable	11,616	13,988
Accrued expenses	30,462	21,365
Interest payable	19,304	14,904
Deferred collaboration revenue	432	2,120
Lease financing obligation	925	1,377
Senior credit facility	19,148	9,020
Non-recourse notes payable	29,890	29,561
Total current liabilities	111,777	92,335
Lease financing obligation	3,919	3,406
Senior credit facility	26,893	41,289
Stockholders’ equity:
Preferred stock, $0.001 par value; shares authorized - 5,000; no shares issued and outstanding	0	0
Common stock, $0.01 par value: shares authorized - 450,000; shares issued and outstanding – 176,566 in 2020 and 154,082 in 2019	1,766	1,541
Additional paid-in capital	994,811	877,300
Accumulated other comprehensive income	9	39
Accumulated deficit	(962,949)	(840,628)
Total stockholders’ equity	33,637	38,252
Total liabilities and stockholders’ equity	$ 176,226	$ 175,282

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	450,000	450,000
Common stock, shares issued (in shares)	176,566	154,082
Common stock, shares outstanding (in shares)	176,566	154,082

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Revenues	$ 6,102	$ 1,775	$ 13,796	$ 9,110
Expenses
Cost of product sales	1,517	0	1,517	1,399
Research and development	30,245	25,120	87,610	80,294
Selling, general and administrative	17,195	11,735	46,943	26,632
Royalty	9	18	78	131
Total operating expenses	48,966	36,873	136,148	108,456
Loss from operations	(42,864)	(35,098)	(122,352)	(99,346)
Interest and other income and expense	(312)	402	8,892	1,545
Interest expense	(2,927)	(3,044)	(8,892)	(8,805)
(Loss) gain on foreign currency derivative	(12)	148	31	331
Net loss	(46,115)	(37,592)	(122,321)	(106,275)
Unrealized gain (loss) on available for sale investments	6	19	(30)	357
Comprehensive loss	$ (46,109)	$ (37,573)	$ (122,351)	$ (105,918)
Basic and diluted net loss per common share (in dollars per share)	$ (0.26)	$ (0.34)	$ (0.75)	$ (0.96)
Weighted average shares outstanding (in shares)	176,521	110,416	164,127	110,308
Product [Member]
Revenues:
Revenues	$ 2,478	$ 335	$ 2,696	$ 2,014
Royalty [Member]
Revenues:
Revenues	254	508	2,243	3,526
Collaborative and Other Research and Development [Member]
Revenues:
Revenues	$ 3,370	$ 932	$ 8,857	$ 3,570

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (122,321)	$ (106,275)
Depreciation and amortization	568	539
Stock-based compensation expense	8,907	14,031
Amortization of debt issuance costs	1,061	936
Amortization of premium/discount on investments	106	1
Change in fair value of foreign currency derivative	630	532
Receivables	16,724	695
Inventory	(6,241)	(127)
Prepaid expenses and other assets	(1,448)	(1,018)
Accounts payable and accrued expenses	6,725	9,975
Interest payable	4,400	1,575
Deferred revenue	(1,688)	0
Net cash used in operating activities	(92,577)	(79,136)
Acquisitions of property and equipment	(359)	(263)
Purchases of investments	(49,818)	(3,018)
Sales and maturities of investments	21,907	64,954
Net cash (used in) provided by investing activities	(28,270)	61,673
Sale of common stock, net	92,848	0
Sale of pre-funded warrants	14,817	0
Proceeds from senior credit facility	0	19,477
Payment of senior credit facility	(5,000)	0
Net proceeds from common stock issued under stock-based compensation plans	1,164	1,161
Net cash provided by financing activities	103,829	20,638
(Decrease) increase in cash, cash equivalents and restricted cash	(17,018)	3,175
Cash, cash equivalents and restricted cash at beginning of period	115,723	28,275
Cash, cash equivalents and restricted cash at end of period	$ 98,705	$ 31,450

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]AOCI Attributable to Parent [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (Accounting Standards Update 2016-02 [Member]) at Dec. 31, 2018	$ 0	$ 0	$ 0	$ 238	$ 238
Balance at Dec. 31, 2018						$ 1,101	$ 780,400	$ (297)	$ (731,969)	$ 49,235
Net loss						0	0	0	(31,054)	(31,054)
Other comprehensive income (loss)						0	0	208	0	208
Employee stock purchase plan sales						0	220	0	0	220
Stock-based compensation expense						0	3,317	0	0	3,317
Exercise of stock options, net						2	341	0	0	343
Balance at Mar. 31, 2019						1,103	784,278	(89)	(762,785)	22,507
Balance (Accounting Standards Update 2016-02 [Member]) at Dec. 31, 2018	$ 0	$ 0	$ 0	$ 238	$ 238
Balance at Dec. 31, 2018						1,101	780,400	(297)	(731,969)	49,235
Net loss										(106,275)
Balance at Sep. 30, 2019						1,104	795,589	60	(838,006)	(41,253)
Balance at Mar. 31, 2019						1,103	784,278	(89)	(762,785)	22,507
Net loss						0	0	0	(37,629)	(37,629)
Other comprehensive income (loss)						0	0	130	0	130
Stock-based compensation expense						0	5,385	0	0	5,385
Exercise of stock options, net						1	413	0	0	414
Balance at Jun. 30, 2019						1,104	790,076	41	(800,414)	(9,193)
Net loss						0	0	0	(37,592)	(37,592)
Other comprehensive income (loss)						0	0	19	0	19
Employee stock purchase plan sales						0	184	0	0	184
Stock-based compensation expense						0	5,329	0	0	5,329
Balance at Sep. 30, 2019						1,104	795,589	60	(838,006)	(41,253)
Balance at Dec. 31, 2019						1,541	877,300	39	(840,628)	38,252
Net loss						0	0	0	(37,599)	(37,599)
Other comprehensive income (loss)						0	0	(25)	0	(25)
Employee stock purchase plan sales						1	265	0	0	266
Stock-based compensation expense						0	2,754	0	0	2,754
Balance at Mar. 31, 2020						1,542	880,319	14	(878,227)	3,648
Balance at Dec. 31, 2019						1,541	877,300	39	(840,628)	38,252
Net loss										(122,321)
Balance at Sep. 30, 2020						1,766	994,811	9	(962,949)	33,637
Balance at Mar. 31, 2020						1,542	880,319	14	(878,227)	3,648
Net loss						0	0	0	(38,607)	(38,607)
Other comprehensive income (loss)						0	0	(11)	0	(11)
Stock-based compensation expense						0	3,280	0	0	3,280
Exercise of stock options, net						2	530	0	0	532
Issuance of common stock, net						220	92,628	0	0	92,848
Issuance of pre-funded warrants, 3,511 warrants						0	14,817	0	0	14,817
Balance at Jun. 30, 2020						1,764	991,574	3	(916,834)	76,507
Net loss						0	0	0	(46,115)	(46,115)
Other comprehensive income (loss)						0	0	6	0	6
Employee stock purchase plan sales						2	364	0	0	366
Stock-based compensation expense						0	2,873	0	0	2,873
Balance at Sep. 30, 2020						$ 1,766	$ 994,811	$ 9	$ (962,949)	$ 33,637

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) - shares	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019
Common Stock [Member]
Employee stock purchase plan sales, shares (in shares)	137,000		110,000	68,000		47,000
Exercise of stock options, shares (in shares)					100,000	160,000
Warrants issued (in shares)		3,511

Note 1 - Significant Accounting

Note 1 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 The Company BioCryst Pharmaceuticals, Inc. (the “Company”) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in 1986, With the funds available at September 30, 2020, second 2021. 2020 2020 2021. may 2021 1 2 3 4 5 one 6 may Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (“Royalty Sub”) and MDCP, LLC (“MDCP”). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on March 9, 2011. 4, September 23, 2016 July 20, 2018 February 5, 2019. 5 The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10 not no These financial statements should be read in conjunction with the financial statements for the year ended December 31, 2019 2019 10 not December 31, 2019 10 Cash and Cash Equivalents The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three Restricted Cash Restricted cash as of September 30, 2020 December 31, 2019 4 Investments The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may three no may may not not not The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not three September 30, 2020, The following tables summarize the fair value of the Company’s investments by type. The estimated fair values of the Company’s fixed income investments are classified as Level 2 not not 2 September 30, 2020 Gross Gross Amortized Accrued Unrealized Unrealized Estimated Cost Interest Gains Losses Fair Value Obligations of U.S. Government and its agencies $ 45,722 $ 18 $ 6 $ - $ 45,746 Corporate debt securities 590 4 - - 594 Certificates of deposit 3,477 9 3 - 3,489 Total investments $ 49,789 $ 31 $ 9 $ - $ 49,829 December 31, 2019 Gross Gross Amortized Accrued Unrealized Unrealized Estimated Cost Interest Gains Losses Fair Value Obligations of U.S. Government and its agencies $ 10,488 50 $ 23 $ - $ 10,561 Corporate debt securities 9,742 59 10 (1 ) 9,810 Certificates of deposit 1,669 7 7 - 1,683 Total investments $ 21,899 116 $ 40 $ (1 ) $ 22,054 The following table summarizes the scheduled maturity for the Company’s investments at September 30, 2020 December 31, 2019. September 30, 2020 December 31, 2019 Maturing in one year or less $ 46,827 $ 22,054 Maturing after one year through two years 3,002 - Total investments $ 49,829 $ 22,054 Receivables from Collaborations Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (“Green Cross”), Mundipharma International Holdings Limited (“Mundipharma”) and Seqirus UK Limited (“SUL”), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2020 December 31, 2019, September 30, 2020 Billed Unbilled Total U.S. Department of Health and Human Services $ - $ 3,547 $ 3,547 Shionogi & Co. Ltd. 1,679 4 1,683 Green Cross Corporation 142 8 150 Mundipharma International Holdings Limited 42 - 42 Total receivables $ 1,863 $ 3,559 $ 5,422 December 31, 2019 Billed Unbilled Total U.S. Department of Health and Human Services $ 1,353 $ 15,023 $ 16,376 Shionogi & Co. Ltd. 1,336 4 1,340 Green Cross Corporation 2,924 8 2,932 Mundipharma International Holdings Limited 56 - 56 Seqirus UK Limited 1,091 351 1,442 Total receivables $ 6,760 $ 15,386 $ 22,146 Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company’s calculations of its indirect cost rates are subject to audit by the U.S. Government. Receivables from Product Sales Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. Inventory Inventory is stated at the lower of cost and net realizable value, determined under the first first September 30, 2020, Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three five seven In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not not Patents and Licenses The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain. Accrued Expenses The Company generally enters into contractual agreements with third not • fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials; • fees paid to investigative sites in connection with clinical trials; • fees paid to contract manufacturers in connection with the production of the Company’s raw materials, drug substance and drug products; and • professional fees. The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may September 30, 2020 December 31, 2019, Income Taxes The liability method is used in the Company’s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Accumulated Other Comprehensive Loss Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders’ equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine September 30, 2020, No nine September 30, 2019. Revenue Recognition Collaborative and Other Research and Development Arrangements and Royalties The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not The Company has collaboration and license agreements with a number of third Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no Arrangements that involve the delivery of more than one not not may Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (”BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred. Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied. Product Sales The Company’s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company’s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. The Company recorded the following revenues for the three nine September 30, 2020 2019: Three Months Nine Months 2020 2019 2020 2019 Product sales $ 2,478 $ 335 $ 2,696 $ 2,014 Royalty revenue 254 508 2,243 3,526 Collaborative and other research and development revenues: U.S. Department of Health and Human Services 3,088 932 7,240 3,570 Torii Pharmaceutical Co., Ltd. 282 — 1,617 — Total collaborative and other research and development revenues 3,370 932 8,857 3,570 Total revenues $ 6,102 $ 1,775 $ 13,796 $ 9,110 Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets. Contract assets Contract liabilities Contract Costs The Company may Advertising The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Research and Development Expenses The Company’s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company’s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company’s manufacturing and clinical and preclinical studies are performed by third Additionally, the Company has license agreements with third Deferred collaboration expenses represent sub-license payments, paid to the Company’s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company’s academic partners for modification to existing license agreements. These deferred expenses would not Stock-Based Compensation All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company’s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no Interest Expense and Deferred Financing Costs Interest expense for the three September 30, 2020 2019 nine September 30, 2020 2019 4 5 three September 30, 2020 2019, nine September 30, 2020, 2019, Currency Hedge Agreement In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not nine September 30, 2020 2019 third not 2 first nine 2020 2019, September 30, 2020 December 31, 2019, no Net Loss Per Share Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company’s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three September 30, 2020 2019 not nine September 30, 2020 2019 not Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Significant Customers and Other Risks Significant Customers Other than royalty revenues, the Company’s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly BCX4430 third Risks from Third Party Manufacturing and Distribution Concentration The Company may Credit Risk Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may no Recent Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments - Credit Losses (Topic 326 Credit Losses on Financial Instruments 2016 13” . 2016 13 2016 13 2016 13 The Company adopted ASU 2016 02 January 1, 2020. not In August 2018, No. 2018 15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350 40 2018 15” 2018 15 2018 15 December 15, 2019, October 1, 2019 not

Note 2 - Stock-based Compensati

Note 2 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 2 As of September 30, 2020, three March 19, 2020 May 12, 2020. April 24, 2019 February 2020 July 2020. March 2020 May 12, 2020. first nine 2020, first nine 2019. There was approximately $21,884 of total unrecognized compensation cost related to non-vested stock option awards granted by the Company as of September 30, 2020. 2020, 2021, 2022, 2023 2024. no Stock Incentive Plan The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after four August 2013, December 2014 December 2019, September 30, 2020, August 2013 September 30, 2020, December 2014 September 30, 2020, none December 2019 nine September 30, 2020, one December 2019 2019, two December 2014 one Related activity under the Incentive Plan is as follows: Weighted Average Awards Options Exercise Available Outstanding Price Balance December 31, 2019 968 21,050 $ 5.96 Plan amendment 8,000 - - Restricted stock unit awards granted (31 ) - - Restricted stock unit awards cancelled - - - Stock option awards granted (547 ) 547 4.86 Stock option awards exercised - (193 ) 2.76 Stock option awards cancelled 3,030 (3,030 ) 6.90 Balance September 30, 2020 11,420 18,374 $ 5.85 For stock option awards granted under the Incentive Plan during the first nine 2020 2019, first nine 2020 2019 Inducement Equity Incentive Plan The Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees are granted with an exercise price equal to the market price of the Company’s stock at the date of grant and generally vest 25% each year until fully vested after four Related activity under the Inducement Plan is as follows: Weighted Average Awards Options Exercise Available Outstanding Price Balance December 31, 2019 171 1,329 $ 3.60 Plan amendment 2,900 - - Stock option awards granted (2,338 ) 2,338 3.33 Stock option awards exercised - - - Stock option awards cancelled 155 (155 ) 4.20 Balance September 30, 2020 888 3,512 $ 3.42 For stock option awards granted under the Inducement Plan during the first nine 2020 2019, first nine 2020 2019 The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan and the Inducement Plan during the first nine 2020 2019, not not zero Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Plans 2020 2019 Expected Life in Years 5.5 5.5 Expected Volatility 83.8 % 81.0 % Expected Dividend Yield 0.0 % 0.0 % Risk-Free Interest Rate 0.4 % 2.0 % Employee Stock Purchase Plan (“ESPP”) The Company has reserved a total of 4,475 shares of common stock to be purchased under the ESPP, of which 2,873 shares remain available for purchase at September 30, 2020. may six No may one six no may one first nine 2020

Note 3 - Collaborative and Othe

Note 3 - Collaborative and Other Research and Development Contracts	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	Note 3 National Institute of Allergy and Infectious Diseases (“NIAID/HHS”). September 2013, 1 April 2020, 19 April 9, 2020, 19. September 30, 2020, 1 August 2020, Biomedical Advanced Research and Development Authority (“BARDA/HHS”). March 31, 2015, September 30, 2020, The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company’s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause. U.S. Department of Health and Human Services (“HHS”) September 6, 2018, 50,000 five two 2019 September 3, 2020, 10,000 Torii Pharmaceutical Co., Ltd. (“Torii”). November 5, 2019, Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000 and may December 31, 2020, December 31, 2021. In addition, the Company will be entitled under the Torii Agreement to receive tiered royalty payments based on the amount of annual net sales of ORLADEYO in Japan during each calendar year. If ORLADEYO maintains its Sakigake designation during the PMDA review, the tiered royalty rate will range from 20% to 40% of net sales; otherwise, the tiered royalty rate will range from 15% to 35% of net sales. Torii’s royalty payment obligations are subject to customary reductions in certain circumstances, but may not first tenth first Under the Torii Agreement, the Company has granted Torii a right of first may not third The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $22,000 606. 2019 two $22,000 2020 Seqirus UK Limited (“SUL”). June 16, 2015, Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA. Pursuant to rights to sell ALPIVAB in the EU, the Company was also responsible for regulatory filings and interactions with the European Medicines Agency (“EMA”). In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development. In October 2017, Under the terms of the SUL Agreement, the Company has received an upfront payment of $33,740 and has achieved all development milestones under the contract totaling $12,000. The Company is entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) The Company and SUL entered arbitration proceedings that involved many items under the SUL Agreement including, but not March 4, 2020, In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties have agreed on a transition process for the product, including a full transition of commercialization of the product in the U.S. to the Company as of August 1, 2020 November 1, 2020. 30 nine September 30, 2020. Shionogi & Co., Ltd. (“Shionogi”). February 2007, October 2008, In December 2017, no Green Cross Corporation (“Green Cross”). June 2006, one Mundipharma International Holdings Limited (“Mundipharma”). February 2006, On November 11, 2011, November 11, 2011, Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (“AECOM” and “IRL” respectively). June 2000, one third may In May 2010, one third not may February 1, 2006 On November 17, 2011, one On June 19, 2012, At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may On January 6, 2014, The University of Alabama at Birmingham (“UAB”). third two five three no

Note 4 - Royalty Monetization

Note 4 - Royalty Monetization	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Royalty Monetization [Text Block]	Note 4 Overview On March 9, 2011, September 2012 As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 not Non-Recourse Notes Payable On March 9, 2011, 2020 March 9, 2011 ( September 1st December 1, 2020, Royalty Sub’s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company’s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, not may one In September 2014, September 3, 2013. September 2013 September 1, 2014, December 31, 2014 may may may not may no not September 30, 2020, The Indenture does not The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed. As of September 30, 2020, 3 Currency Hedge Agreement In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar. The Currency Hedge Agreement does not nine September 30, 2020 2019

Note 5 - Senior Credit Facility

Note 5 - Senior Credit Facility	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 On February 5, 2019, three first second third second third September 10, 2019 first second November 30, 2019. November 30, 2019, second The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of July 20, 2018 ( not June 2020 As of September 30, 2020, Principal Payments 2020 $ 5,000 2021 20,000 2022 20,000 Total $ 45,000 The debt agreement contains two not

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 6 On April 24, 2020, 3 May 14, 2020 June 1, 2020, 30

Note 7 - Lease Obligations and

Note 7 - Lease Obligations and Other Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Leases of Lessor Disclosure [Text Block]	Note 7 The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases at September 30, 2020. 2023 2026. September 30, 2020, The Company has not no Aggregate lease expense under operating leases was $1,321 and $1,064 for the nine September 30, 2020 September 30, 2019, twelve not Future lease payments for assets under operating leases as of September 30, 2020, Remaining Maturities of Lease Liabilities Year Ending December 31, Operating Leases 2020 $ 403 2021 851 2022 746 2023 608 2024 577 Thereafter 7,908 Total lease payments 11,093 Less imputed interest 6,249 Total $ 4,844 Of the Company’s total lease liability, $925 is a current liability and $3,919 is a long-term liability at September 30, 2020. September 30, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Description of Company [Policy Text Block]	The Company BioCryst Pharmaceuticals, Inc. (the “Company”) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in 1986, With the funds available at September 30, 2020, second 2021. 2020 2020 2021. may 2021 1 2 3 4 5 one 6 may
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (“Royalty Sub”) and MDCP, LLC (“MDCP”). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on March 9, 2011. 4, September 23, 2016 July 20, 2018 February 5, 2019. 5 The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10 not no These financial statements should be read in conjunction with the financial statements for the year ended December 31, 2019 2019 10 not December 31, 2019 10
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Restricted cash as of September 30, 2020 December 31, 2019 4
Investment, Policy [Policy Text Block]	Investments The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may three no may may not not not The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not three September 30, 2020, The following tables summarize the fair value of the Company’s investments by type. The estimated fair values of the Company’s fixed income investments are classified as Level 2 not not 2 September 30, 2020 Gross Gross Amortized Accrued Unrealized Unrealized Estimated Cost Interest Gains Losses Fair Value Obligations of U.S. Government and its agencies $ 45,722 $ 18 $ 6 $ - $ 45,746 Corporate debt securities 590 4 - - 594 Certificates of deposit 3,477 9 3 - 3,489 Total investments $ 49,789 $ 31 $ 9 $ - $ 49,829 December 31, 2019 Gross Gross Amortized Accrued Unrealized Unrealized Estimated Cost Interest Gains Losses Fair Value Obligations of U.S. Government and its agencies $ 10,488 50 $ 23 $ - $ 10,561 Corporate debt securities 9,742 59 10 (1 ) 9,810 Certificates of deposit 1,669 7 7 - 1,683 Total investments $ 21,899 116 $ 40 $ (1 ) $ 22,054 The following table summarizes the scheduled maturity for the Company’s investments at September 30, 2020 December 31, 2019. September 30, 2020 December 31, 2019 Maturing in one year or less $ 46,827 $ 22,054 Maturing after one year through two years 3,002 - Total investments $ 49,829 $ 22,054
Receivable [Policy Text Block]	Receivables from Collaborations Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (“Green Cross”), Mundipharma International Holdings Limited (“Mundipharma”) and Seqirus UK Limited (“SUL”), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2020 December 31, 2019, September 30, 2020 Billed Unbilled Total U.S. Department of Health and Human Services $ - $ 3,547 $ 3,547 Shionogi & Co. Ltd. 1,679 4 1,683 Green Cross Corporation 142 8 150 Mundipharma International Holdings Limited 42 - 42 Total receivables $ 1,863 $ 3,559 $ 5,422 December 31, 2019 Billed Unbilled Total U.S. Department of Health and Human Services $ 1,353 $ 15,023 $ 16,376 Shionogi & Co. Ltd. 1,336 4 1,340 Green Cross Corporation 2,924 8 2,932 Mundipharma International Holdings Limited 56 - 56 Seqirus UK Limited 1,091 351 1,442 Total receivables $ 6,760 $ 15,386 $ 22,146 Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company’s calculations of its indirect cost rates are subject to audit by the U.S. Government.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost and net realizable value, determined under the first first September 30, 2020,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three five seven In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Licenses The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.
Accrued Expenses [Policy Text Block]	Accrued Expenses The Company generally enters into contractual agreements with third not • fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials; • fees paid to investigative sites in connection with clinical trials; • fees paid to contract manufacturers in connection with the production of the Company’s raw materials, drug substance and drug products; and • professional fees. The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may September 30, 2020 December 31, 2019,
Income Tax, Policy [Policy Text Block]	Income Taxes The liability method is used in the Company’s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.
Comprehensive Income, Policy [Policy Text Block]	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders’ equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine September 30, 2020, No nine September 30, 2019.
Revenue [Policy Text Block]	Revenue Recognition Collaborative and Other Research and Development Arrangements and Royalties The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not The Company has collaboration and license agreements with a number of third Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no Arrangements that involve the delivery of more than one not not may Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (”BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred. Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied. Product Sales The Company’s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company’s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. The Company recorded the following revenues for the three nine September 30, 2020 2019: Three Months Nine Months 2020 2019 2020 2019 Product sales $ 2,478 $ 335 $ 2,696 $ 2,014 Royalty revenue 254 508 2,243 3,526 Collaborative and other research and development revenues: U.S. Department of Health and Human Services 3,088 932 7,240 3,570 Torii Pharmaceutical Co., Ltd. 282 — 1,617 — Total collaborative and other research and development revenues 3,370 932 8,857 3,570 Total revenues $ 6,102 $ 1,775 $ 13,796 $ 9,110 Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets. Contract assets Contract liabilities Contract Costs The Company may Advertising The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses The Company’s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company’s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company’s manufacturing and clinical and preclinical studies are performed by third Additionally, the Company has license agreements with third Deferred collaboration expenses represent sub-license payments, paid to the Company’s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company’s academic partners for modification to existing license agreements. These deferred expenses would not
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company’s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no
Interest Expense and Deferred Financing Costs [Policy Text Block]	Interest Expense and Deferred Financing Costs Interest expense for the three September 30, 2020 2019 nine September 30, 2020 2019 4 5 three September 30, 2020 2019, nine September 30, 2020, 2019,
Currency Hedge Agreement [Policy Text Block]	Currency Hedge Agreement In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not nine September 30, 2020 2019 third not 2 first nine 2020 2019, September 30, 2020 December 31, 2019, no
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company’s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three September 30, 2020 2019 not nine September 30, 2020 2019 not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
Concentration of Market Risk [Policy Text Block]	Significant Customers and Other Risks Significant Customers Other than royalty revenues, the Company’s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly BCX4430 third Risks from Third Party Manufacturing and Distribution Concentration The Company may Credit Risk Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments - Credit Losses (Topic 326 Credit Losses on Financial Instruments 2016 13” . 2016 13 2016 13 2016 13 The Company adopted ASU 2016 02 January 1, 2020. not In August 2018, No. 2018 15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350 40 2018 15” 2018 15 2018 15 December 15, 2019, October 1, 2019 not

Note 1 - Significant Accounti_2

Note 1 - Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Debt Securities, Available-for-sale [Table Text Block]	September 30, 2020 Gross Gross Amortized Accrued Unrealized Unrealized Estimated Cost Interest Gains Losses Fair Value Obligations of U.S. Government and its agencies $ 45,722 $ 18 $ 6 $ - $ 45,746 Corporate debt securities 590 4 - - 594 Certificates of deposit 3,477 9 3 - 3,489 Total investments $ 49,789 $ 31 $ 9 $ - $ 49,829 December 31, 2019 Gross Gross Amortized Accrued Unrealized Unrealized Estimated Cost Interest Gains Losses Fair Value Obligations of U.S. Government and its agencies $ 10,488 50 $ 23 $ - $ 10,561 Corporate debt securities 9,742 59 10 (1 ) 9,810 Certificates of deposit 1,669 7 7 - 1,683 Total investments $ 21,899 116 $ 40 $ (1 ) $ 22,054
Available For Sale Securities Debt Maturities Fair Value [Table Text Block]	September 30, 2020 December 31, 2019 Maturing in one year or less $ 46,827 $ 22,054 Maturing after one year through two years 3,002 - Total investments $ 49,829 $ 22,054
Schedule of Receivables from Collaborations [Table Text Block]	September 30, 2020 Billed Unbilled Total U.S. Department of Health and Human Services $ - $ 3,547 $ 3,547 Shionogi & Co. Ltd. 1,679 4 1,683 Green Cross Corporation 142 8 150 Mundipharma International Holdings Limited 42 - 42 Total receivables $ 1,863 $ 3,559 $ 5,422 December 31, 2019 Billed Unbilled Total U.S. Department of Health and Human Services $ 1,353 $ 15,023 $ 16,376 Shionogi & Co. Ltd. 1,336 4 1,340 Green Cross Corporation 2,924 8 2,932 Mundipharma International Holdings Limited 56 - 56 Seqirus UK Limited 1,091 351 1,442 Total receivables $ 6,760 $ 15,386 $ 22,146
Disaggregation of Revenue [Table Text Block]	Three Months Nine Months 2020 2019 2020 2019 Product sales $ 2,478 $ 335 $ 2,696 $ 2,014 Royalty revenue 254 508 2,243 3,526 Collaborative and other research and development revenues: U.S. Department of Health and Human Services 3,088 932 7,240 3,570 Torii Pharmaceutical Co., Ltd. 282 — 1,617 — Total collaborative and other research and development revenues 3,370 932 8,857 3,570 Total revenues $ 6,102 $ 1,775 $ 13,796 $ 9,110

Note 2 - Stock-based Compensa_2

Note 2 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Weighted Average Awards Options Exercise Available Outstanding Price Balance December 31, 2019 968 21,050 $ 5.96 Plan amendment 8,000 - - Restricted stock unit awards granted (31 ) - - Restricted stock unit awards cancelled - - - Stock option awards granted (547 ) 547 4.86 Stock option awards exercised - (193 ) 2.76 Stock option awards cancelled 3,030 (3,030 ) 6.90 Balance September 30, 2020 11,420 18,374 $ 5.85 Weighted Average Awards Options Exercise Available Outstanding Price Balance December 31, 2019 171 1,329 $ 3.60 Plan amendment 2,900 - - Stock option awards granted (2,338 ) 2,338 3.33 Stock option awards exercised - - - Stock option awards cancelled 155 (155 ) 4.20 Balance September 30, 2020 888 3,512 $ 3.42
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Expected Life in Years 5.5 5.5 Expected Volatility 83.8 % 81.0 % Expected Dividend Yield 0.0 % 0.0 % Risk-Free Interest Rate 0.4 % 2.0 %

Note 5 - Senior Credit Facili_2

Note 5 - Senior Credit Facility (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Principal Payments 2020 $ 5,000 2021 20,000 2022 20,000 Total $ 45,000

Note 7 - Lease Obligations an_2

Note 7 - Lease Obligations and Other Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lessee, Lease, Liability, Maturity [Table Text Block]	Remaining Maturities of Lease Liabilities Year Ending December 31, Operating Leases 2020 $ 403 2021 851 2022 746 2023 608 2024 577 Thereafter 7,908 Total lease payments 11,093 Less imputed interest 6,249 Total $ 4,844

Note 1 - Significant Accounti_3

Note 1 - Significant Accounting Policies (Details Textual) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 23, 2016	Mar. 09, 2011
Long-term Line of Credit, Total	$ 26,893		$ 26,893		$ 41,289
Restricted Cash and Cash Equivalents, Current, Total	2,213		2,213		1,551
Inventory, Raw Materials, Net of Reserves	206		206
Inventory, Work in Process, Net of Reserves	6,035		6,035
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			1	$ 0
Interest Expense, Debt, Total	2,927	$ 3,044	8,892	8,805
Amortization of Debt Issuance Costs	$ 381	$ 341	$ 1,061	$ 936
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	16,544	541	14,154	1,892
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative, Loss on Derivative			$ 630	$ 532
Derivative, Gain on Derivative			660	$ 863
Currency Hedge Agreement [Member]
Collateral Already Posted, Aggregate Fair Value	$ 0		$ 0		0
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Laboratory Equipment, Office Equipment and Software [Member]
Property, Plant and Equipment, Useful Life (Year)			5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)			7 years
Maximum [Member]
Maturity Period of High Quality Marketable Securities (Year)			3 years
Average Maturity Period of High Quality Marketable Securities (Month)			18 months
Maturity Period of Short Term Investment (Month)			12 months
Average Maturity for Portfolio Investments (Month)			18 months
Minimum [Member]
Long-term Investment Maturity, Minimum (Month)			12 months
Royalty Receivable [Member]
Restricted Cash and Cash Equivalents, Current, Total	795		$ 795		134
Collateral for Credit [Member]
Restricted Cash and Cash Equivalents, Current, Total	1,418		1,418		$ 1,417
Senior Credit Facility [Member] | MidCap Financial Services, LLC [Member]
Long-term Line of Credit, Total	$ 45,000		$ 45,000			$ 23,000
JPR Royalty Sub LLC [Member]
Revenue Recognition Royalty and Milestone Revenue Recognized							$ 30,000

Note 1 - Significant Accounti_4

Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Amortized Cost	$ 49,789,000	$ 21,899,000
Accrued Interest	31,000	116,000
Gross Unrealized Gains	9,000	40,000
Gross Unrealized Losses	0	(1,000)
Estimated Fair Value	49,829,000	22,054,000
US Government Agencies Debt Securities [Member]
Amortized Cost	45,722,000	10,488,000
Accrued Interest	18,000	50,000
Gross Unrealized Gains	6,000	23,000
Gross Unrealized Losses	0	0
Estimated Fair Value	45,746,000	10,561,000
Corporate Debt Securities [Member]
Amortized Cost	590	9,742,000
Accrued Interest	4	59,000
Gross Unrealized Gains	0	10,000
Gross Unrealized Losses	0	(1,000)
Estimated Fair Value	594	9,810,000
Certificates of Deposit [Member]
Amortized Cost	3,477,000	1,669,000
Accrued Interest	9,000	7,000
Gross Unrealized Gains	3,000	7,000
Gross Unrealized Losses	0	0
Estimated Fair Value	$ 3,489,000	$ 1,683,000

Note 1 - Significant Accounti_5

Note 1 - Significant Accounting Policies - Scheduled Maturity for the Company's Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Maturing in one year or less	$ 46,827	$ 22,054
Maturing after one year through two years	3,002	0
Total investments	$ 49,829	$ 22,054

Note 1 - Significant Accounti_6

Note 1 - Significant Accounting Policies - Summary of Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Receivables	$ 5,422	$ 22,146
Billed Revenues [Member]
Receivables	1,863	6,760
Unbilled Revenues [Member]
Receivables	3,559	15,386
US Department of Health and Human Services [Member]
Receivables	3,547	16,376
US Department of Health and Human Services [Member] | Billed Revenues [Member]
Receivables	0	1,353
US Department of Health and Human Services [Member] | Unbilled Revenues [Member]
Receivables	3,547	15,023
Shionogi and Co. Ltd [Member]
Receivables	1,683	1,340
Shionogi and Co. Ltd [Member] | Billed Revenues [Member]
Receivables	1,679	1,336
Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]
Receivables	4	4
Green Cross Corporation [Member]
Receivables	150	2,932
Green Cross Corporation [Member] | Billed Revenues [Member]
Receivables	142	2,924
Green Cross Corporation [Member] | Unbilled Revenues [Member]
Receivables	8	8
Mundipharma International Holdings Limited [Member]
Receivables	42	56
Mundipharma International Holdings Limited [Member] | Billed Revenues [Member]
Receivables	42	56
Mundipharma International Holdings Limited [Member] | Unbilled Revenues [Member]
Receivables	$ 0	0
Seqirus UK Limited [Member]
Receivables		1,442
Seqirus UK Limited [Member] | Billed Revenues [Member]
Receivables		1,091
Seqirus UK Limited [Member] | Unbilled Revenues [Member]
Receivables		$ 351

Note 1 - Significant Accounti_7

Note 1 - Significant Accounting Policies - Summary of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenues	$ 6,102	$ 1,775	$ 13,796	$ 9,110
Torii Pharmaceutical Co. [Member]
Revenues					$ 20,101
Product [Member]
Revenues	2,478	335	2,696	2,014
Royalty [Member]
Revenues	254	508	2,243	3,526
Collaborative and Other Research and Development [Member]
Revenues	3,370	932	8,857	3,570
Collaborative and Other Research and Development [Member] | US Department of Health and Human Services [Member]
Revenues	3,088	932	7,240	3,570
Collaborative and Other Research and Development [Member] | Torii Pharmaceutical Co. [Member]
Revenues	$ 282	$ 0	$ 1,617	$ 0

Note 2 - Stock-based Compensa_3

Note 2 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			9 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2014	Aug. 31, 2013	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share-based Payment Arrangement, Expense				$ 8,907	$ 14,031
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				21,884
Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year				2,708
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year				8,461
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two				6,983
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three				3,137
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four				595
Incentive Plan [Member]
Share-based Payment Arrangement, Expense				$ 7,492	$ 13,635
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	968,000			11,420,000		968,000
Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 3.35	$ 4.57
Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)				10 years
Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Vest 25% Each Year Until Fully Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				4 years
Incentive Plan [Member] | Performance Shares [Member] | December 2014 [Member]
Share-based Payment Arrangement, Expense						$ 4,998
Incentive Plan [Member] | Performance Shares [Member] | December 2019 [Member]
Share-based Payment Arrangement, Expense				$ 214
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)				0
Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	315,000	1,250,000	1,032,000
Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				75.00%
Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				85.00%
Inducement Plan [Member]
Share-based Payment Arrangement, Expense				$ 1,053	$ 164
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	171,000			888,000		171,000
Inducement Plan [Member] | Vest 25% Each Year Until Fully Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%
Inducement Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 2.41	$ 2.72
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Employee Stock Purchase Plan [Member]
Share-based Payment Arrangement, Expense				$ 362	$ 232
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				4,475,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)				2,873,000
Percentage of Salary to Purchase Common Stock, Maximum				15.00%
Percentage of Common Stock Shares, Beginning				85.00%
Percentage of Common Stock Shares, Ending				85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)				3,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount				$ 25
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)				246

Note 2 - Stock-based Compensa_4

Note 2 - Stock-based Compensation - Stock Plan Activities (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Incentive Plan [Member]
Awards available, beginning balance (in shares)	968
Options outstanding, beginning balance (in shares)	21,050
Weighted average exercise price, beginning balance (in dollars per share) | $ / shares	$ 5.96
Awards, available, Plan amendment (in shares)	8,000
Awards available, Restricted stock unit awards granted (in shares)	(31)
Awards available, Restricted stock unit awards cancelled (in shares)	0
Awards available, stock option awards granted (in shares)	(547)
Options outstanding, stock option awards granted (in shares)	547
Weighted average exercise price, stock option awards granted (in dollars per share) | $ / shares	$ 4.86
Options outstanding, stock option awards exercised (in shares)	(193)
Weighted average exercise price, stock option awards exercised (in dollars per share) | $ / shares	$ 2.76
Awards available, stock option awards cancelled (in shares)	3,030
Options outstanding, stock option awards cancelled (in shares)	(3,030)
Weighted average exercise price, stock option awards cancelled (in dollars per share) | $ / shares	$ 6.90
Awards available, ending balance (in shares)	11,420
Options outstanding, ending balance (in shares)	18,374
Weighted average exercise price, ending balance (in dollars per share) | $ / shares	$ 5.85
Inducement Plan [Member]
Awards available, beginning balance (in shares)	171
Options outstanding, beginning balance (in shares)	1,329
Weighted average exercise price, beginning balance (in dollars per share) | $ / shares	$ 3.60
Awards, available, Plan amendment (in shares)	2,900
Awards available, stock option awards granted (in shares)	(2,338)
Options outstanding, stock option awards granted (in shares)	2,338
Weighted average exercise price, stock option awards granted (in dollars per share) | $ / shares	$ 3.33
Options outstanding, stock option awards exercised (in shares)	0
Weighted average exercise price, stock option awards exercised (in dollars per share) | $ / shares	$ 0
Awards available, stock option awards cancelled (in shares)	155
Options outstanding, stock option awards cancelled (in shares)	(155)
Weighted average exercise price, stock option awards cancelled (in dollars per share) | $ / shares	$ 4.20
Awards available, ending balance (in shares)	888
Options outstanding, ending balance (in shares)	3,512
Weighted average exercise price, ending balance (in dollars per share) | $ / shares	$ 3.42

Note 2 - Stock-based Compensa_5

Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details) - Incentive Plan and Inducement Plan [Member]	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Expected Life (Year)	5 years 6 months	5 years 6 months
Expected Volatility	83.80%	81.00%
Expected Dividend Yield	0.00%	0.00%
Risk-Free Interest Rate	0.40%	2.00%

Note 3 - Collaborative and Ot_2

Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual) - USD ($) $ in Thousands

Sep. 03, 2020

Mar. 04, 2020

Nov. 05, 2019

Sep. 06, 2018

Jun. 16, 2015

Feb. 28, 2006

Aug. 31, 2020

Sep. 30, 2013

Jun. 30, 2006

Jun. 30, 2000

Sep. 30, 2020

Sep. 30, 2019

Jun. 30, 2020

Sep. 30, 2020

Sep. 30, 2019

Dec. 31, 2019

Sep. 30, 2020

Sep. 30, 2020

Mar. 31, 2015

Nov. 11, 2011

Revenue from Contract with Customer, Including Assessed Tax

$ 6,102

$ 1,775

$ 13,796

$ 9,110

Arbitration Proceedings of SUL Agreement [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 5,000

Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member]

Gain (Loss) Related to Litigation Settlement, Total

8,893

Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member]

Legal Fees

$ 5,026

US Department of Health and Human Services [Member]

Collaborative Agreement Contract Value

$ 34,660

Contract Term (Year)

5 years

Proceeds from Collaborators

$ 6,932

$ 13,864

Torii Pharmaceutical Co. [Member]

Upfront Payments Receivable Amount

$ 22,000

Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2020

20,000

Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021

$ 15,000

Maximum Customary Reduction on Royalty Rate

50.00%

Royalty Payments Receivable, Expiration Term From First Commercial (Year)

10 years

Revenue from Contract with Customer, Including Assessed Tax

20,101

Torii Pharmaceutical Co. [Member] | License [Member]

Revenue from Contract with Customer, Including Assessed Tax

19,344

Torii Pharmaceutical Co. [Member] | Service [Member]

Revenue from Contract with Customer, Including Assessed Tax

$ 757

Torii Pharmaceutical Co. [Member] | Minimum [Member]

Royalty Rate if Maintains Sakigake Designation

20.00%

Royalty Rate, Otherwise

15.00%

Torii Pharmaceutical Co. [Member] | Maximum [Member]

Royalty Rate if Maintains Sakigake Designation

40.00%

Royalty Rate, Otherwise

35.00%

CSL Limited [Member

Proceeds from License Fees Received

$ 33,740

Milestone Payment Received

$ 12,000

Base Contract [Member]

Government Contract Receivable

$ 16,265

Additional Development Options [Member]

Government Contract Receivable

22,855

ASPRBARDA Contract [Member]

Government Contract Receivable

$ 39,120

Proceeds from awards for Research and Development Contracts

$ 20,574

Green Cross Corporation [Member]

Proceeds from License Fees Received

$ 250

Mundipharma [Member]

Upfront Payments Receivable Amount

$ 10,000

Potential Milestone Payments Receivable

$ 15,000

AECOM and IRL [Member]

Milestone Payment Minimum

$ 1,400

Milestone Payment Maximum

4,000

Annual License Fee Minimum

150

Annual License Fee Maximum

$ 500

Advance Notice Period for Termination of Agreement (Day)

60 days

National Institute of Allergy and Infectious Diseases [Member]

Collaborative Agreement Contract Value

$ 6,326

$ 5,000

Expected Receivable From Awards for Research and Development Contracts

$ 45,931

Collaborative Agreement Contract, Covenant, Maximum Amount of Funding

$ 43,908

UAB [Member]

Period of Agreement (Year)

25 years

Renewable Period of Agreement (Year)

5 years

Note 3 - Collaborative and Ot_3

Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual) - Torii Pharmaceutical Co. [Member] - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 $ in Thousands	Sep. 30, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 1,899
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	6 months

Note 4 - Royalty Monetization (

Note 4 - Royalty Monetization (Details Textual) $ in Thousands	Mar. 09, 2011USD ($)	Sep. 30, 2020USD ($)¥ / $	Sep. 30, 2019USD ($)
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative, Loss on Derivative		$ 630	$ 532
PhaRMA Notes Member] | Currency Hedge Agreement [Member]
Derivative, Forward Exchange Rate (in JPY per USD) | ¥ / $		100
JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]
Private Placement of Senior Secured Notes	$ 30,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Percentage of Carrying Amount in Excess of Fair Value		3.00%
JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]
Notes Payable, Fair Value Disclosure		$ 30,000
JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]
Debt Instrument, Face Amount	$ 30,000
Proceeds from Issuance of Secured Debt	22,691
Transaction Costs	4,309
Interest Reserve	$ 3,000

Note 5 - Senior Credit Facili_3

Note 5 - Senior Credit Facility (Details Textual) - USD ($) $ in Thousands	Feb. 05, 2019	Sep. 30, 2020	Dec. 31, 2019	Sep. 23, 2016
Long-term Line of Credit, Total		$ 26,893	$ 41,289
MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member]
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Minimum LIBOR	0.50%
Debt Instrument, Term (Month)	30 months
Line of Credit, Restricted Cash Required	$ 25,000
Long-term Line of Credit, Total		$ 45,000		$ 23,000
Line of Credit Facility, Interest Rate at Period End		8.50%
MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	8.00%
MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | Secured Credit Facility, First Tranche [Member]
Debt Instrument, Face Amount	$ 50,000
Repayments of Long-term Debt, Total	30,000
MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | Secured Credit Facility, Second Tranche [Member]
Debt Instrument, Face Amount	30,000
MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | Secured Credit Facility, Third Tranche [Member]
Debt Instrument, Face Amount	$ 20,000

Note 5 - Senior Credit Facili_4

Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details) $ in Millions	Sep. 30, 2020USD ($)
2020	$ 5
2021	20
2022	20
Total	$ 45

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jun. 01, 2020	Apr. 24, 2020
Maximum Aggregate Offering Price		$ 500,000
Stock Issued During Period, Shares, New Issues (in shares)	22,044,447
Shares Issued, Price Per Share (in dollars per share)	$ 4.50
Proceeds from Issuance or Sale of Equity, Total	$ 107,665
Warrants Issued in Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,511,111
Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)	$ 4.49
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01

Note 7 - Lease Obligations an_3

Note 7 - Lease Obligations and Other Contingencies (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating Lease, Weighted Average Remaining Lease Term (Year)	13 years 8 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent	12.80%
Operating Lease, Expense	$ 1,321	$ 1,064
Accrued Liabilities, Current [Member]
Operating Lease, Liability, Current	925
Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Noncurrent	3,919
Other Noncurrent Assets [Member]
Operating Lease, Right-of-Use Asset	$ 3,646
Minimum [Member]
Lessee, Operating Lease, Term of Contract (Year)	1 year
Maximum [Member]
Lessee, Operating Lease, Term of Contract (Year)	5 years

Note 7 - Lease Obligations an_4

Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2020USD ($)
2020	$ 403
2021	851
2022	746
2023	608
2024	577
Thereafter	7,908
Total lease payments	11,093
Less imputed interest	6,249
Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]
Total	$ 4,844